HUYA Bioscience Announces Agreement to Provide Schering-Plough With Drug Development Candidates ... (BI-3000 and HBI-8000. Both drugs for car...)

HUYA Bioscience Announces Agreement to Provide Schering-Plough With Drug Development Candidates From China

Date:12/15/2008

BI-3000 and HBI-8000. Both drugs, for cardiac fibrillation and oncology, respectively, have successfully passed US FDA pre-IND consultations.

HUYA's Innovative Co-Development Model

HUYA was one of the first companies to recognize China's potential to help meet the global need for pre-clinical and clinical stage compounds for the drug development process. Leveraging the HUYA Integrated Co-development Model for partnering with Chinese research institutions and pharmaceutical companies, HUYA identifies and licenses highly promising pre-clinical and clinical stage compounds in China. HUYA's Chinese partners retain development and marketing rights in China with the expectation that both parties will benefit from the research and development collaboration.

One of the key differentiators of HUYA's approach HUYA is the assembly of a high-level team of scientific and clinical advisors for each new compound. The team collaborates with its' Chinese partners to discuss and design clinical trials as the compounds enter the U.S. development process, speeding the process and mitigating risk. HUYA's global team of advisors includes Benedict Lucchesi, MD, PhD, Peter R. Kowey, MD, Dennis Roy, MD, Jefferson L. Anderson, MD, Eric J. Topol, MD, Stanley Nattel, MD, Anthony Tolcher, MD, Alex Adjei, MD, PhD, Patricia LoRusso, DO and Michael Robertson, MD.

"From my involvement with the cardiac fibrillation program, I have been impressed with the relationship that HUYA has forged with its Chinese partners," said Eric Topol, MD, Chief Academic Officer, Scripps Health, San Diego, CA. "HUYA's co-development model is an excellent system for developing new drugs and ultimately introducing them into the Western market."

About HUYA

HUYA is a leader in U.S./China pharmaceutical co-development with three strategic offices in China, a broad Chinese compound port
'/>"/>

0

GOOD

Page: 1 2 3
Related biology technology :

1. Pressure BioSciences, Inc. and Omni International Announce Marketing, Distribution, and Technology Development Agreement
2. YM BIOSCIENCES PROVIDES EU REGULATORY UPDATE
3. CeloNova BioSciences Commercializes CATANIA(TM) Coronary Stent With NanoThin Polyzene(R)-F in Europe and Middle East
4. DuPont Applied BioSciences Selects MBI to Collaborate on Process Development and Scale-Up for New Bio-based Product
5. Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer
6. Frost & Sullivan Recognizes Martek Biosciences for Unique and Customer-Focused Strategies With Customer Value Enhancement Award
7. PURE Bioscience and Ciba Strike New Contract for Natural Antimicrobial
8. Regado Biosciences to Present at the Piper Jaffray Health Care Conference on Tuesday, December 2, 2008
9. Sangamo BioSciences to Webcast Annual Investor and Analyst Briefing and Presentation at Piper Jaffray Health Care Conference
10. Cyntellect Appoints Former BD Biosciences Executive Andre Lubarsky as Director of Sales - North America
11. Neurocrine Biosciences to Present at the 20th Annual Piper Jaffray Health Care Conference

Post Your Comments:

HUYA Bioscience Announces Agreement to Provide Schering-Plough With Drug Development Candidates ...(BI-3000 and HBI-8000. Both drugs for car...)